GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Investments And Advances

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Investments And Advances : €0.00 Mil (As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings Investments And Advances?

Oxford Cannabinoid Technologies Holdings's Investments And Advances for the quarter that ended in Oct. 2023 was €0.00 Mil.


Oxford Cannabinoid Technologies Holdings Investments And Advances Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Investments And Advances Chart

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
Investments And Advances
- - - - -

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
Investments And Advances Get a 7-Day Free Trial Premium Member Only - - - - -

Oxford Cannabinoid Technologies Holdings Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines